Agilent and BGI to Collaborate on Next-Generation Super Array for Disease and Drug Research
News Feb 28, 2012
Agilent Technologies Inc. and BGI has announced a collaborative effort to develop methodologies designated for next-generation genome-wide association studies.
The methodologies will assist scientists pursuing disease and drug research.
The goal of the collaboration is to create a next-generation super exome, using Agilent’s SureSelect technology.
The super exome incorporates sequence regions believed to be more informative for specific human populations.
BGI is the largest genome sequencing center in Asia and one of the largest genomics research centers in the world.
“BGI aims to develop research collaborations and provide support to scientists all over the world,” said Hui Jiang, associate director of the Science and Technology Department at BGI.
Jiang continued, “Together with Agilent’s expertise, we can create more precise and accurate technology that can be deployed in large-scale research to better understand complex diseases, which may have differences between ethnicities.”
As part of this collaboration, BGI has selected to use Agilent’s comprehensive portfolio of solutions for genomics research and next-generation sequencing tools.
These include Agilent’s SureSelect target-enrichment system and Agilent’s 2100 bioanalyzers. Additionally, Agilent will grant BGI early access to newly developed tools for the sequencing space.
“Agilent has a comprehensive portfolio of market-leading solutions for genomics research,” said Robert Schueren, vice president and general manager of Agilent's genomics business.
Schueren continued, “This partnership with BGI will not only add to this portfolio, but also further Agilent's mission to build products that enable life sciences discoveries and develop solutions that improve the human condition."
BGI and Agilent have been working closely together over the years. Previously, BGI used Agilent’s technologies to streamline and enhance the throughput of BGI's next-generation sequencing workflow. In China, BGI became the country’s first certified SureSelect XT service provider.
Agent Reverses Resistance to Targeted Drug in Some LeukemiasNews
After discovering how some hematologic cancer cells manage to elude death from a targeted therapy, Dana-Farber Cancer Institute scientists have double-crossed the cancer cells with a drug that renders them vulnerable to the targeted agent.READ MORE
Progressive Kidney Disease: New Compound Restores Kidney FunctionNews
A team led by researchers describe a new approach to prevent death in these essential kidney cells. Studying multiple animal models of kidney disease, the team discovered a compound that can impede loss of the filtration cells and restore kidney function.READ MORE
New Drug Delivery System Targets Diseases at a Genetic LevelNews
A new drug delivery system that uses a synthetic-biological hybrid nanocapsule could provide a smart technology for targeted treatment of a variety of serious diseases at the genetic level.